🇺🇸 FDA
Pipeline program

Sodium Zirconium Cyclosilicate (SZC)

D9487C00001

Phase 3 small_molecule terminated

Quick answer

Sodium Zirconium Cyclosilicate (SZC) for Hyperkalemia is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Hyperkalemia
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials